These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 704768)

  • 1. Striatal membrane 3H-dopamine binding in an animal model of tardive dyskinesia.
    Klawans HL; Hitri A
    Psychopharmacol Bull; 1978 Oct; 14(4):72-6. PubMed ID: 704768
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine binding following prolonged haloperidol pretreatment.
    Hitri A; Weiner WJ; Borison RL; Diamond BI; Nausieda PA; Klawans HL
    Ann Neurol; 1978 Feb; 3(2):134-40. PubMed ID: 655662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models for tardive dyskinesia: effects of thioridazine.
    Sayers AC; Bürki HR; Ruch W; Asper H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):291-5. PubMed ID: 616929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
    Koller WC
    J Clin Psychopharmacol; 1984 Dec; 4(6):343-5. PubMed ID: 6512004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia.
    Delfs JM; Ellison GD; Mercugliano M; Chesselet MF
    Exp Neurol; 1995 Jun; 133(2):175-88. PubMed ID: 7544289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of drug holidays in an animal model of tardive dyskinesia.
    Bannet J; Belmaker RH; Ebstein RP
    Psychopharmacology (Berl); 1980; 69(2):223-4. PubMed ID: 6779315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
    Koller W; Curtin J; Fields J
    Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
    J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.
    Rizos EN; Chatziioannou S; Siafakas N; Douzenis A; Katsantoni E; Mandrapilia A; Bacalis S; Fotiadis C; Lykouras L
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1135-6. PubMed ID: 20460141
    [No Abstract]   [Full Text] [Related]  

  • 14. Animal models of tardive dyskinesia: their use in the search for new treatment methods.
    Goetz CG; Klawans HL; Carvey P
    Mod Probl Pharmacopsychiatry; 1983; 21():5-20. PubMed ID: 6140633
    [No Abstract]   [Full Text] [Related]  

  • 15. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
    Silverdale MA; Crossman AR; Brotchie JM
    Exp Neurol; 2002 Mar; 174(1):21-8. PubMed ID: 11869030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
    Friedhoff AJ; Bonnet K; Tosengarten H
    Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium interferes with reserpine-induced dopamine depletion.
    Reches A; Hassan MN; Jackson V; Fahn S
    Ann Neurol; 1983 Jun; 13(6):671-3. PubMed ID: 6410976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.